心脏手术患者吸入依前列醇联合米力农的肺血管扩张反应
该回顾性队列研究纳入128例合并肺动脉高压或右心室功能障碍的体外循环心脏手术患者,在CPB前给予吸入依前列醇联合米力农(iE&iM)。77.3%患者出现阳性肺血管扩张反应;基线收缩期肺动脉压是阳性反应的预测因子,EuroSCORE II >6.5%是非反应的预测因子。
要点
- CPB前吸入iE&iM后77.3%患者出现阳性肺血管扩张反应。
- 基线收缩期肺动脉压升高是阳性反应的预测因子。
- EuroSCORE II >6.5%预示对iE&iM治疗无反应。
核心结论
- CPB前吸入依前列醇联合米力农在77%患者中观察到阳性肺血管扩张反应。
- 较高基线收缩期肺动脉压是肺血管扩张反应的独立预测因子,EuroSCORE II >6.5%是非反应的预测因子。
研究设计与样本
- 回顾性队列研究,纳入2013年7月至2018年12月在Montreal Heart Institute接受体外循环心脏手术的连续肺动脉高压或右心室功能障碍患者128例。
- iE&iM在CPB开始前通过超声网孔雾化器给药。
- 阳性反应定义为平均动脉压与平均肺动脉压比值增加20%。
主要发现
- 77.3%患者对iE&iM治疗为阳性反应者。
关键数值与推荐
- 阳性肺血管扩张反应定义为平均动脉压与平均肺动脉压比值增加20%。
临床怎么用
- 对合并肺动脉高压或右心室功能障碍的心脏手术患者,可考虑在CPB前经雾化吸入依前列醇联合米力农以辅助脱离CPB。
- 基线收缩期肺动脉压较高者更可能从iE&iM治疗中获益。
- EuroSCORE II >6.5%的患者对iE&iM治疗反应可能性较低。
局限性
- 本研究为回顾性队列研究。
- 单中心研究,样本量128例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary hypertension (PH) and right ventricular (RV) dysfunction are major complications in cardiac surgery. Intraoperative management of patients at high risk of RV failure should aim to reduce RV afterload and optimize RV filling pressures, while avoiding systemic hypotension, to facilitate weaning from cardiopulmonary bypass (CPB). Inhaled epoprostenol and inhaled milrinone (iE&iM) administered in combination before CPB may represent an effective strategy to facilitate separation from CPB and reduce requirements for intravenous inotropes during cardiac surgery. Our primary objective was to report the rate of positive pulmonary vasodilator response to iE&iM and, second, how it relates to perioperative outcomes in cardiac surgery. METHODS: This is a retrospective cohort study of consecutive patients with PH or RV dysfunction undergoing on-pump cardiac surgery at the Montreal Heart Institute from July 2013 to December 2018 (n = 128). iE&iM treatment was administered using an ultrasonic mesh nebulizer before the initiation of CPB. Demographic and baseline clinical data, as well as hemodynamic, intraoperative, and echocardiographic data, were collected using electronic records. An increase of 20% in the mean arterial pressure (MAP) to mean pulmonary artery pressure (MPAP) ratio was used to indicate a positive response to iE&iM. RESULTS: In this cohort, 77.3% of patients were responders to iE&iM treatment. Baseline systolic pulmonary artery pressure (SPAP) (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.24-2.16 per 5 mm Hg; P = .0006) was found to be a predictor of pulmonary vasodilator response, while a European System for Cardiac Operative Risk Evaluation (EuroSCORE II) score >6.5% was a predictor of nonresponse to treatment (≤6.5% vs >6.5% [reference]: OR, 5.19; 95% CI, 1.84-14.66; P = .002). Severity of PH was associated with a positive response to treatment, where a higher proportion of responders had MPAP values >30 mm Hg (42.4% responders vs 24.1% nonresponders; P = .0237) and SPAP values >55 mm Hg (17.2% vs 3.4%; P = .0037). Easier separation from CPB was also associated with response to iE&iM treatment (69.7% vs 58.6%; P = .0181). A higher proportion of nonresponders had a very difficult separation from CPB and required intravenous inotropic drug support compared to responders, for whom easy separation from CPB was more frequent. Use of intravenous inotropes after CPB was lower in responders to treatment (8.1% vs 27.6%; P = .0052). CONCLUSIONS: A positive pulmonary vasodilator response to treatment with a combination of iE&iM before initiation of CPB was observed in 77% of patients. Higher baseline SPAP was an independent predictor of pulmonary vasodilator response, while EuroSCORE II >6.5% was a predictor of nonresponse to treatment.
引用
- Elmi-Sarabi M, Jarry S, Couture EJ, et al. Pulmonary Vasodilator Response of Combined Inhaled Epoprostenol and Inhaled Milrinone in Cardiac Surgical Patients. Anesth Analg. 2022. PMID: 36121254. doi:10.1213/ANE.0000000000006192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。